Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma

Antoine Digonnet, Marc Hamoir, Guy Andry, Missak Haigentz, Robert P. Takes, Carl E. Silver, Dana M. Hartl, Primož Strojan, Alessandra Rinaldo, Remco De Bree, Andreas Dietz, Vincent Grégoire, Vinidh Paleri, Johannes A. Langendijk, Vincent Vander Poorten, Michael L. Hinni, Juan P. Rodrigo, Carlos Suárez, William M. Mendenhall, Jochen A. WernerEric M. Genden, Alfio Ferlito

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2-6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.

Original languageEnglish (US)
Pages (from-to)1569-1580
Number of pages12
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume270
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Tomography
Cost-Benefit Analysis
Thorax
Therapeutics
Nutritional Status
Radiography
Carcinoma, squamous cell of head and neck
Consensus
Radiotherapy
Rehabilitation
Magnetic Resonance Imaging
Guidelines
Psychology
Recurrence
Pain
Neoplasms

Keywords

  • Distant metastasis
  • Head and neck cancer
  • HPV
  • Recurrence
  • Surveillance strategy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Digonnet, A., Hamoir, M., Andry, G., Haigentz, M., Takes, R. P., Silver, C. E., ... Ferlito, A. (2013). Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 270(5), 1569-1580. https://doi.org/10.1007/s00405-012-2172-7

Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. / Digonnet, Antoine; Hamoir, Marc; Andry, Guy; Haigentz, Missak; Takes, Robert P.; Silver, Carl E.; Hartl, Dana M.; Strojan, Primož; Rinaldo, Alessandra; De Bree, Remco; Dietz, Andreas; Grégoire, Vincent; Paleri, Vinidh; Langendijk, Johannes A.; Vander Poorten, Vincent; Hinni, Michael L.; Rodrigo, Juan P.; Suárez, Carlos; Mendenhall, William M.; Werner, Jochen A.; Genden, Eric M.; Ferlito, Alfio.

In: European Archives of Oto-Rhino-Laryngology, Vol. 270, No. 5, 05.2013, p. 1569-1580.

Research output: Contribution to journalArticle

Digonnet, A, Hamoir, M, Andry, G, Haigentz, M, Takes, RP, Silver, CE, Hartl, DM, Strojan, P, Rinaldo, A, De Bree, R, Dietz, A, Grégoire, V, Paleri, V, Langendijk, JA, Vander Poorten, V, Hinni, ML, Rodrigo, JP, Suárez, C, Mendenhall, WM, Werner, JA, Genden, EM & Ferlito, A 2013, 'Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma', European Archives of Oto-Rhino-Laryngology, vol. 270, no. 5, pp. 1569-1580. https://doi.org/10.1007/s00405-012-2172-7
Digonnet, Antoine ; Hamoir, Marc ; Andry, Guy ; Haigentz, Missak ; Takes, Robert P. ; Silver, Carl E. ; Hartl, Dana M. ; Strojan, Primož ; Rinaldo, Alessandra ; De Bree, Remco ; Dietz, Andreas ; Grégoire, Vincent ; Paleri, Vinidh ; Langendijk, Johannes A. ; Vander Poorten, Vincent ; Hinni, Michael L. ; Rodrigo, Juan P. ; Suárez, Carlos ; Mendenhall, William M. ; Werner, Jochen A. ; Genden, Eric M. ; Ferlito, Alfio. / Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. In: European Archives of Oto-Rhino-Laryngology. 2013 ; Vol. 270, No. 5. pp. 1569-1580.
@article{d38156bbecc145eb8b1b8b87081a207f,
title = "Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma",
abstract = "The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2-6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.",
keywords = "Distant metastasis, Head and neck cancer, HPV, Recurrence, Surveillance strategy",
author = "Antoine Digonnet and Marc Hamoir and Guy Andry and Missak Haigentz and Takes, {Robert P.} and Silver, {Carl E.} and Hartl, {Dana M.} and Primož Strojan and Alessandra Rinaldo and {De Bree}, Remco and Andreas Dietz and Vincent Gr{\'e}goire and Vinidh Paleri and Langendijk, {Johannes A.} and {Vander Poorten}, Vincent and Hinni, {Michael L.} and Rodrigo, {Juan P.} and Carlos Su{\'a}rez and Mendenhall, {William M.} and Werner, {Jochen A.} and Genden, {Eric M.} and Alfio Ferlito",
year = "2013",
month = "5",
doi = "10.1007/s00405-012-2172-7",
language = "English (US)",
volume = "270",
pages = "1569--1580",
journal = "Archives of Otolaryngology",
issn = "2168-6181",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma

AU - Digonnet, Antoine

AU - Hamoir, Marc

AU - Andry, Guy

AU - Haigentz, Missak

AU - Takes, Robert P.

AU - Silver, Carl E.

AU - Hartl, Dana M.

AU - Strojan, Primož

AU - Rinaldo, Alessandra

AU - De Bree, Remco

AU - Dietz, Andreas

AU - Grégoire, Vincent

AU - Paleri, Vinidh

AU - Langendijk, Johannes A.

AU - Vander Poorten, Vincent

AU - Hinni, Michael L.

AU - Rodrigo, Juan P.

AU - Suárez, Carlos

AU - Mendenhall, William M.

AU - Werner, Jochen A.

AU - Genden, Eric M.

AU - Ferlito, Alfio

PY - 2013/5

Y1 - 2013/5

N2 - The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2-6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.

AB - The management of head and neck squamous cell carcinomas does not end with the completion of ablative therapy. The oncologic objectives of post-treatment follow-up are to detect recurrences and second primary tumors; beyond that, follow-up should evaluate acute and chronic treatment-related side effects, guide the rehabilitation process, alleviate functional loss, manage pain, restore nutritional status and assess psychosocial factors. In this structured review, we address the questions of timing and the tools required to achieve a complete and coherent routine surveillance. Several guidelines and consensus statements recommend clinical examination as the cornerstone of follow-up which should be performed for at least 5 years, although there are no data in favor of any one particular follow-up program, and only low-level evidence suggests an improvement in oncologic outcomes by close follow-up. Baseline imaging (computed tomography and magnetic resonance imaging) should be obtained within 2-6 months after definitive therapy if used for treatment response evaluation. Metabolic response, if indicated, should be assessed preferably after 3 months in patients who undergo curative-intent therapy with (chemo)-radiotherapy. Chest computed tomography is more sensitive than plain radiography, if used in follow-up, but the benefit and cost-effectiveness of routine chest computed tomography has not been demonstrated. There are no current data supporting modifications specific to the surveillance plan of patients with human papillomavirus-associated disease.

KW - Distant metastasis

KW - Head and neck cancer

KW - HPV

KW - Recurrence

KW - Surveillance strategy

UR - http://www.scopus.com/inward/record.url?scp=84877154331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877154331&partnerID=8YFLogxK

U2 - 10.1007/s00405-012-2172-7

DO - 10.1007/s00405-012-2172-7

M3 - Article

C2 - 22972497

AN - SCOPUS:84877154331

VL - 270

SP - 1569

EP - 1580

JO - Archives of Otolaryngology

JF - Archives of Otolaryngology

SN - 2168-6181

IS - 5

ER -